# Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT

> **NCT06865144** · PHASE4 · RECRUITING · sponsor: **East Coast Institute for Research** · enrollment: 70 (estimated)

## Conditions studied

- Primary Open Angle Glaucoma or Ocular Hypertension

## Interventions

- **DRUG:** Netarsudil ophthalmic solution 0.02%
- **DRUG:** Artificial tears

## Key facts

- **NCT ID:** NCT06865144
- **Lead sponsor:** East Coast Institute for Research
- **Sponsor class:** NETWORK
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-27
- **Primary completion:** 2026-04-01
- **Final completion:** 2026-04-01
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-07-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06865144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06865144, "Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT06865144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*